InsiderTrades

Form 4 for AKTS Aktis Oncology, Inc.

Accepted 2026-07-10 06:11:06 ET · period of report 2026-07-08 · accession 0001193125-26-300163 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-07-10 06:11 2026-07-08 AKTS Ron-Bigger Shulamit COO M - OptEx $3.66 +50.0K 50.0K New +$183.0K
DM 2026-07-10 06:11 2026-07-08 AKTS Ron-Bigger Shulamit COO S - Sale+OE $27.75 -50.0K 0 -100% -$1.39M
D 2026-07-10 06:11 2026-07-08 AKTS Ron-Bigger Shulamit COO M - OptEx $0.00 -50.0K 217.9K -19% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-07-08 M A 50,000 $3.66 50,000 D — —
2 Common Common Stock 2026-07-08 S D 15,800 $27.13 34,200 D — — (F1) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.5200 to $27.5100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3 Common Common Stock 2026-07-08 S D 30,000 $27.94 4,200 D — — (F2) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.5200 to $28.4700, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
4 Common Common Stock 2026-07-08 S D 4,200 $28.75 0 D — — (F3) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.7300 to $28.7600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
5 Derivative Stock Option (Right to Buy) 2026-07-08 M D 50,000 $0.00 217,888 D $3.66 · — to 2032-10-30 50,000 Common Stock (F4) 25% of the original number of shares subject to the option vested on September 19, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.